Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters











Publication year range
1.
J Chromatogr B Biomed Sci Appl ; 691(2): 463-71, 1997 Apr 11.
Article in English | MEDLINE | ID: mdl-9174285

ABSTRACT

An achiral HPLC method using a silica gel column as well as two independent chiral analytical methods by HPLC and capillary zone electrophoresis (CZE) were developed in order to investigate the in vitro metabolism of the racemic antiasthmatic/antiallergic drug flezelastine. The chiral HPLC analysis was performed on a Chiralpak AD column, which also allowed the simultaneous separation of the N-dephenethyl metabolite. The chiral separation by CZE was achieved by the addition of beta-cyclodextrin to the run buffer. The stereoselectivity of the in vitro biotransformation of flezelastine was investigated using liver homogenates of different species. Depending on the species, diverse stereoselective aspects were demonstrated. The determination of the enantiomeric ratios of flezelastine and of N-dephenethylflezelastine after incubations of racemic flezelastine with liver microsomes revealed that porcine liver microsomes showed the greatest enantioselectivity of the biotransformation. (-)-Flezelastine was preferentially metabolized. After incubations with bovine liver microsomes the enantiomer of N-dephenethylflezelastine formed from (+)-flezelastine dominated. Incubations of the pure enantiomers of flezelastine with induced rat liver microsomes resulted in the stereoselective formation of a hitherto unknown metabolite, which was only detected in samples of (+)-flezelastine. Initial structure elucidation of the compound indicated that the new metabolite was most likely an aromatically hydroxylated derivative of the N-dephenethylflezelastine.


Subject(s)
Anti-Allergic Agents/metabolism , Anti-Asthmatic Agents/metabolism , Azepines/metabolism , Phthalazines/metabolism , Animals , Anti-Allergic Agents/analysis , Anti-Asthmatic Agents/analysis , Azepines/analysis , Biotransformation , Cattle , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/metabolism , Electrophoresis, Capillary , Humans , In Vitro Techniques , Male , Mass Spectrometry , Microsomes, Liver/chemistry , Microsomes, Liver/metabolism , Phthalazines/analysis , Rats , Rats, Sprague-Dawley , Species Specificity , Stereoisomerism , Swine
2.
Chirality ; 9(1): 32-6, 1997.
Article in English | MEDLINE | ID: mdl-9094201

ABSTRACT

A specific plasma level assay for the enantiomers of alpha-lipoic acid is described. It makes use of liquid-liquid extraction, chemical reduction to the dithiol enantiomers, and their precolumn chiral derivatisation with o-phthalaldehyde in the presence of D-phenylalanine. The two diastereomeric derivatives are separated by reversed-phase HPLC with fluorescence detection. The working range of the assay is between 15 ng/ml (lower limit of quantitation) and 1,000 ng/ml for either enantiomer.


Subject(s)
Thioctic Acid/blood , Calibration , Chromatography, High Pressure Liquid/methods , Humans , Reference Standards , Spectrometry, Fluorescence , Stereoisomerism
3.
Biochim Biophys Acta ; 1297(1): 90-8, 1996 Sep 13.
Article in English | MEDLINE | ID: mdl-8841385

ABSTRACT

The strain Escherichia coli JRG26, which has a defect in the lipoic acid biosynthesis, was cultivated in the presence of R-lipoic acid, S-lipoic acid, RS-dithiolane-3-caproic acid, RS-bisnorlipoic acid, and RS-tetranorlipoic acid, respectively. With the exception of the last compound the strain was able to grow with all these substances. R-lipoic acid was the most efficient factor, concentrations of 10 ng/l were sufficient to support growth of the cells, while 10(4)-fold to 10(7)-fold higher concentrations were necessary for the other compounds. The specific catalytic activity of the pyruvate dehydrogenase complex isolated from the cells grown on RS-dithiolane-3-caproic acid was only slightly lower than from cells grown on R-lipoic acid. With RS bisnorlipoic acid the specific activity was one third compared to that of the native enzyme complex. The incorporation of the RS-bisnorlipoic acid into the pyruvate dehydrogenase could directly be demonstrated by polyclonal antibodies directed against R-lipoic acid and RS-bisnorlipoic acid, both conjugated to BSA. Western blot analysis showed that the antibodies against the R-lipoic acid reacted specifically with the E2 component of pyruvate dehydrogenase complex purified from cells grown on this factor, while antibodies against RS-bisnorlipoic acid reacted with the enzyme complex isolated from cells grown in the presence of this compound.


Subject(s)
Acetyltransferases/metabolism , Escherichia coli/enzymology , Pyruvate Dehydrogenase Complex/metabolism , Thioctic Acid/metabolism , Binding Sites , Dihydrolipoyllysine-Residue Acetyltransferase , Escherichia coli/growth & development , Precipitin Tests , Stereoisomerism , Thioctic Acid/analogs & derivatives
4.
FEBS Lett ; 371(2): 167-70, 1995 Sep 04.
Article in English | MEDLINE | ID: mdl-7672120

ABSTRACT

The thioredoxin-catalyzed insulin reduction by dihydrolipoate was applied to study the 2-oxoacid: lipoate oxidoreductase activity of 2-oxoacid dehydrogenase complexes. The enzymatic and non-enzymatic mechanisms of the transfer of reducing equivalents from the complexes to free lipoic acid (alpha-lipoic acid, 6,8-thiooctic acid) were distinguished using the high stereoselectivity of the complex enzymes to the R-enantiomer of lipoate. Unlike these enzymes, thioredoxin from E. coli exhibited no stereoselectivity upon reduction with chemically obtained dihydrolipoate. However, coupled to the dihydrolipoate production by the dehydrogenase complexes, the process was essentially sensitive both to the enantiomer used and the dihydrolipoyl dehydrogenase activity of the complexes. These results indicated the involvement of the third complex component, dihydrolipoyl dehydrogenase, in the 2-oxoacid-dependent dihydrolipoate formation. The implication of the investigated reaction for a connection between thioredoxin and the 2-oxoacid dehydrogenase complexes in the mitochondrial metabolism are discussed.


Subject(s)
Ketoglutaric Acids/pharmacology , Ketone Oxidoreductases/metabolism , Multienzyme Complexes/metabolism , Thioctic Acid/analogs & derivatives , Thioctic Acid/metabolism , Thioredoxins/metabolism , 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) , Biphenyl Compounds/pharmacology , Chemical Precipitation , Escherichia coli/enzymology , Flavin-Adenine Dinucleotide/metabolism , Flavin-Adenine Dinucleotide/pharmacology , Insulin/metabolism , Ketoglutarate Dehydrogenase Complex/metabolism , NAD/pharmacology , Onium Compounds/pharmacology , Pyruvate Dehydrogenase Complex/metabolism , Stereoisomerism
5.
Biochem Pharmacol ; 50(5): 637-46, 1995 Aug 25.
Article in English | MEDLINE | ID: mdl-7669066

ABSTRACT

Lipoic acid (alpha-lipoic acid, thioctic acid) is applied as a therapeutic agent in various diseases accompanied by polyneuropathia such as diabetes mellitus. The stereoselectivity and specificity of lipoic acid for the pyruvate dehydrogenase complex and its component enzymes from different sources has been studied. The dihydrolipoamide dehydrogenase component from pig heart has a clear preference for R-lipoic acid, a substrate which reacts 24 times faster than the S-enantiomer. Selectivity is more at the stage of the catalytic reaction than of binding. The Michaelis constants of both enantiomers are comparable (Km = 3.7 and 5.5 mM for R- and S-lipoic acid, respectively) and the S-enantiomer inhibits the R-lipoic acid dependent reaction with an inhibition constant similar to its Michaelis constant. When three lipoic acid homologues were tested, RS-1,2-dithiolane-3-caproic acid was one carbon atom longer than lipoic acid, while RS-bisnorlipoic acid and RS-tetranorlipoic acid were two and four carbon atoms shorter, respectively. All are poor substrates but bind to and inhibit the enzyme with an affinity similar to that of S-lipoic acid. No essential differences with respect to its reaction with lipoic acid enantiomers and homologues exist between free and complex-bound dihydrolipoamide dehydrogenase. Dihydrolipoamide dehydrogenase from human renal carcinoma has a higher Michaelis constant for R-lipoic acid (Km = 18 mM) and does not accept the S-enantiomer as a substrate. Both enantiomers of lipoic acid are inhibitors of the overall reaction of the bovine pyruvate dehydrogenase complex, but stimulate the respective enzyme complexes from rat as well as from Escherichia coli. The S-enantiomer is the stronger inhibitor, the R-enantiomer the better activator. The two enantiomers have no influence on the partial reaction of the bovine pyruvate dehydrogenase component, but do inhibit this enzyme component from rat kidney. The implications of these results are discussed.


Subject(s)
Pyruvate Dehydrogenase Complex/metabolism , Thioctic Acid/metabolism , Animals , Cattle , Dihydrolipoamide Dehydrogenase/antagonists & inhibitors , Dihydrolipoamide Dehydrogenase/metabolism , Humans , Kidney Neoplasms/enzymology , Kinetics , Myocardium/enzymology , Rats , Stereoisomerism , Substrate Specificity , Swine , Thioctic Acid/chemistry
6.
Arzneimittelforschung ; 45(5): 576-81, 1995 May.
Article in English | MEDLINE | ID: mdl-7612056

ABSTRACT

The tolerability and pharmacokinetics of azelastine hydrochloride (CAS 73907-93-0, A-05610) after single and multiple dosing (4.4 mg as tablet, tau = 12 h) were investigated in 14 volunteers (6 female, 8 male) older than 65 years (70 +/- 5 years, mean +/- SD). The medication was administered as tablets in the morning of days 1 and 11, and b.i.d. on days 4 to 10 in a randomized, open-labelled, uncontrolled study. Tolerance proved to be very good. Reported number of adverse events was independent from height of plasma levels measured, which showed pronounced inter- and intraindividual variation. When comparing pharmacokinetic parameters from plasma levels (determined with a radioimmunoassay (RIA)) of the elderly with those of young volunteers (26 +/- 5 years), there is a difference in half lives (t1/2 elderly vs young: single dose: 38.5 +/- 15.3 h vs 25.0 +/- 5.2 h; multiple dose: 35.5 +/- 16.3 h vs 55.4 +/- 24.9 h), and also after a single dose AUC and after multiple dosing AUCss tau, tssmax, Cssmax, Cssmin (pre dose levels), and the ratios of accumulation Rmax and Rmin (calculated from Cssmax/Cmax and Cssmin/Cmin) are approximately twice as high in elderly as those in young volunteers. The RIA co-detects besides azelastine the pharmacodynamically active metabolite N-demethyl-azelastine and thus, the parameters describe the pharmacokinetic behaviour as a resultant from both compounds, i.e. the "active principle". N-Demethylated metabolites are known to have longer half-lives usually than their parent compounds and thus, accumulate in a higher degree during multiple dosing.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Phthalazines/adverse effects , Phthalazines/pharmacokinetics , Adult , Aged , Aging/metabolism , Double-Blind Method , Female , Half-Life , Humans , Male
7.
Arzneimittelforschung ; 45(3): 293-9, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7741788

ABSTRACT

rac-a-Lipoic acid (CAS 62-46-4, thioctic acid) is used in human therapy besides the parenteral route also orally in gastric juice soluble galenic formulations in patients suffering from diabetic polyneuropathy which also involves the gastrointestinal tract (GI) tract in about 20% of the diabetic population. In those patients the most common manifestation of the disease due to small intestine dysfunction is diarrhoea as a consequence of which malabsorption of orally administered drugs may result. Due to the importance of the knowledge on absorption characteristics, in preclinical studies on pharmacokinetics the extent of [14C]absorption from a solution of [7,8-14C]rac-a-lipoic acid was investigated in the rat after oral administration by means of comparison of the AUCs from the [14C]plasma concentrations vs those from the intravenous route, yielding 66%. An alternative evaluation by comparison of [14C]material excreted into the urine yielded 93% [14C]absorption. Despite this high and nearly complete absorption, due to the gastroenteral disturbances mentioned above, the question was investigated if the absorption is restricted to only a small area of the GI tract or is extended over a wider area. The latter is expected to make the absorption less sensitive against variations caused by gastrointestinal disturbances due to longer residence times in the GI tract. In order to approach most closely the physiological situation--as compared with different in vitro incubation techniques using isolated GI tract sacs--the in situ technique on 5 ligated areas of the GI tract of the aneasthetized rat (stomach, duodenum, jejunum, ileum, and colon with caecum) was established.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Intestinal Absorption/physiology , Thioctic Acid/pharmacokinetics , Administration, Oral , Animals , Chemical Phenomena , Chemistry, Physical , Injections, Intravenous , Male , Rats , Rats, Sprague-Dawley , Thioctic Acid/administration & dosage , Thioctic Acid/chemistry
8.
Arzneimittelforschung ; 44(10): 1136-40, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7818588

ABSTRACT

In a double-blind, randomized, 4-period crossover study, single oral doses of azelastine hydrochloride tablets (A-05610, Allergodil, Radethazin, Azeptin, CAS 79307-93-0) were ingested by 12 healthy volunteers (6 males, 6 females, mean age 25.2 +/- 3.5 years). Dose linearity was demonstrated for 2.2, 4.4, 8.8 and 17.6 mg of azelastine hydrochloride. The values of AUC0-infinity and Cmax increased linear to the dose (means of AUC0-infinity: 47.3, 93.7, 208.0 and 405.90 ng-eq h/ml; means of Cmax: 1.5, 3.3, 6.0 and 12.5 ng-eq/ml), whereas tmax and the terminal half-life of elimination (t1/2 beta) were obviously not influenced by the dose. Mean values over all doses and subjects amounted to 4.6 h (tmax) and 25.5 h (t1/2 beta). Plasma levels showed relatively high inter- and somewhat less intraindividual variations. This is most likely due to a varying degree of enterohepatic circulation resulting from alimentary factors. As for the co-detection of azelastine and the pharmacodynamically active metabolite N-desmethyl-azelastine by the radio-immuno-assay (RIA) used, the parameters describe the pharmacokinetic behaviour as a resultant from both compounds and thus the active principle of the drug. Independently of the dosages administered the overall tolerance proved to be very good. According to this trial the therapeutic range is wide enough to recommend 4.4 mg b.i.d. or single doses of 8.8 mg of azelastine hydrochloride per day for therapy in adult patients.


Subject(s)
Histamine H1 Antagonists/adverse effects , Histamine H1 Antagonists/pharmacokinetics , Phthalazines/adverse effects , Phthalazines/pharmacokinetics , Adult , Double-Blind Method , Female , Half-Life , Histamine H1 Antagonists/administration & dosage , Humans , Male , Phthalazines/administration & dosage , Radioimmunoassay , Sex Characteristics
9.
J Chromatogr B Biomed Appl ; 653(1): 102-5, 1994 Feb 18.
Article in English | MEDLINE | ID: mdl-8012552

ABSTRACT

This is the first paper which describes a HPLC method for the determination of the decapeptide cetrorelix, a potent luteinizing hormone-releasing hormone (LH-RH) antagonist, in human plasma by liquid-liquid extraction, concentration by back-extraction with diluted acid into a smaller volume, and fluorescence detection, using the decapeptide D-21740 as internal standard. The excitation (227 nm) and emission wavelengths (340 nm) for cetrorelix and the internal standard are identical. The extraction yield for both peptides is ca. 50% and the assay is linear over the concentration range 2-20 ng/ml in plasma. The mobile phase components are ammonium acetate buffer (0.05 mol/l, pH 4) as solvent A and methanol-acetonitrile (1:1, v/v) as solvent B. The elution condition for the peptides from the column (Lichrospher 60 RP-Select B 5 microns, 250 x 4 mm I.D.) is isocratic with a 49:51 mixture of solvent A-solvent B. The lower limit of quantitation for cetrorelix is 2 ng/ml human plasma.


Subject(s)
Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Amino Acid Sequence , Chromatography, High Pressure Liquid , Gonadotropin-Releasing Hormone/administration & dosage , Gonadotropin-Releasing Hormone/blood , Gonadotropin-Releasing Hormone/pharmacokinetics , Humans , Indicators and Reagents , Injections, Intravenous , Injections, Subcutaneous , Molecular Sequence Data , Solutions , Spectrometry, Fluorescence
10.
Eur J Clin Pharmacol ; 46(3): 271-4, 1994.
Article in English | MEDLINE | ID: mdl-8070510

ABSTRACT

Naftopidil exerts its antihypertensive action via alpha 1-adrenoceptor blockage and Ca2+ antagonism in vascular smooth muscle. Since the chemically similar 1-(1-naphthyl) piperazine is known to be a 5-hydroxytryptamine2 receptor antagonist, the 5-hydroxytryptamine (5-HT) antagonistic properties of naftopidil were tested by examining 5-HT-induced aggregation and 5-HT uptake in platelets from 12 healthy volunteers after oral administration of 60 mg naftopidil or placebo. Platelet aggregation in vitro was inhibited by naftopidil with a Ki value of 1.1 microM, the pIC50 was 5.09 with induction of aggregation by 1 microM 5-HT. After oral administration of naftopidil, 5-HT-induced aggregation was significantly inhibited by 36%. 4 h after naftopidil administration, 5-HT uptake velocity was reduced by 33%. Naftopidil not only cancelled the circadian increase in 5-HT-induced aggregation velocity observed during placebo application, but also caused a decrease in aggregation velocity directly after peak plasma naftopidil levels. 5-HT uptake in platelets was also reduced following peak naftopidil plasma concentrations. The 5-HT inhibitory action of naftopidil adds a third possible antihypertensive property to naftopidil's alpha 1-adrenoceptor blocking and Ca2+ antagonistic properties.


Subject(s)
Calcium Channel Blockers/pharmacology , Naphthalenes/pharmacology , Piperazines/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin Antagonists/pharmacology , Serotonin/pharmacology , Adult , Blood Pressure/drug effects , Calcium Channel Blockers/adverse effects , Double-Blind Method , Heart Rate/drug effects , Humans , Male , Naphthalenes/adverse effects , Piperazines/adverse effects , Platelet Aggregation Inhibitors/adverse effects , Serotonin Antagonists/adverse effects , Selective Serotonin Reuptake Inhibitors/adverse effects
11.
J Cardiovasc Pharmacol ; 20(6): 1006-13, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1282583

ABSTRACT

The interaction of naftopidil with adrenoceptors was studied in comparison to standard drugs. Naftopidil binds specifically to alpha 1-adrenoceptors. The Ki values are 58.3 nM for naftopidil, 0.43 nM for prazosin, and 197 nM for urapidil. The affinities of naftopidil to alpha 2- and beta-adrenoceptor sites are very low (> 6,000 and > 2,500 nM). Naftopidil relaxes aortic strips precontracted with norepinephrine concentration-dependently, and it shifts the concentration-response curve of norepinephrine in a parallel manner to the right. The pA2 values are 7.10 for naftopidil, 8.85 for prazosin, and 6.25 for urapidil. In pithed rats, naftopidil shifted the dose-response curve of methoxamine at equipotent hypotensive doses to the same extent to the right as does prazosin, but both drugs barely affected (in contrast to phentolamine) the response to norepinephrine. In concentrations that are about 10 times higher than those required for alpha 1-adrenoceptor blockade, naftopidil relaxes (in contrast to prazosin) aortic strips depolarized with K+, and it shifts Ca2+ concentration-response curves to the right (pA2 value of 5.90), thus suggesting Ca(2+)-channel-blocking activity. Both alpha-adrenoceptor and Ca(2+)-blocking activities are exerted to nearly the same extent by both stereoisomers. Naftipidil does not affect the response to isoprenaline-induced effects, indicating that the compound does not possess beta-blocking properties.


Subject(s)
Adrenergic alpha-Antagonists/pharmacology , Calcium Channel Blockers/pharmacology , Naphthalenes/pharmacology , Piperazines/pharmacology , Receptors, Adrenergic/drug effects , Adrenergic alpha-Antagonists/metabolism , Adrenergic beta-Antagonists/pharmacology , Animals , Binding, Competitive/drug effects , Blood Pressure/drug effects , Calcium Channel Blockers/metabolism , Decerebrate State/physiopathology , In Vitro Techniques , Male , Muscle Relaxation/drug effects , Muscle, Smooth, Vascular/drug effects , Naphthalenes/metabolism , Norepinephrine/pharmacology , Piperazines/metabolism , Propranolol/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic/metabolism , Vasodilation/drug effects
12.
Arzneimittelforschung ; 42(11): 1343-5, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1492848

ABSTRACT

Single oral doses of the non-opioid, centrally-acting analgesic flupirtine maleate (Katadolon, CAS 75507-68-5) were administered to healthy volunteers and the 2 h plasma levels determined with a new specific HPLC assay. 50, 100, 200, and 300 mg were ingested as the commercial capsules in a double-blind randomized cross-over design with time intervals of at least 6 d. Dose-proportionality was observed for the median 2 h plasma levels which is in agreement with dose-proportionality previously described for multiple-dose studies.


Subject(s)
Aminopyridines/blood , Analgesics/blood , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Double-Blind Method , Humans
13.
J Cardiovasc Pharmacol ; 18(6): 918-25, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1725907

ABSTRACT

The newly developed antihypertensive agent naftopidil blocks alpha 1-adrenoceptors and inhibits Ca2+ entry via potential-dependent channels in vascular and cardiac muscle. It is extensively metabolized in vivo. Since it is of interest whether its metabolites are still pharmacologically active, we have characterized the effects of (naphthyl)hydroxy-naftopidil (NHN), (phenyl)hydroxy-naftopidil (PHN), and O-desmethyl-naftopidil (DMN) in various isolated preparations of the guinea pig heart. In constant-flow Langendorff hearts, the compounds decreased force of contraction by 66-81% and slowed spontaneous heart rate by 28-48%. DMN reduced perfusion pressure by 33%. The fibrillation threshold, which was measured as the strength of alternating current required to induce ventricular fibrillation, increased more than 10-fold. In papillary muscles, 3 x 10(-5) M of all compounds reduced force of contraction (pD2 values approximately 5.5) and shortened the action potential duration in the plateau phase. The maximum depolarization velocity (dV/dtmax) was slightly reduced (10-21%) by NHN, PHN, and DMN. In voltage-clamped ventricular cardiomyocytes, the calcium current ICa was depressed by the three compounds (10(-6)-10(-4) M) in a concentration-dependent manner. In conclusion, the three naftopidil metabolites investigated have pharmacological activities similar to those of their parent compound and hence could contribute to the in vivo effects of naftopidil.


Subject(s)
Adrenergic alpha-Antagonists/metabolism , Antihypertensive Agents/pharmacology , Calcium Channel Blockers/pharmacology , Naphthalenes/metabolism , Naphthalenes/pharmacology , Naphthols/pharmacology , Piperazines/metabolism , Piperazines/pharmacology , Animals , Guinea Pigs , In Vitro Techniques , Male , Papillary Muscles/drug effects , Papillary Muscles/physiology
14.
Eur J Pharmacol ; 205(1): 105-7, 1991 Nov 19.
Article in English | MEDLINE | ID: mdl-1839829

ABSTRACT

Naftopidil, a novel antihypertensive compound, possesses 5-HT1A agonistic properties in addition to being an alpha 1-adrenoceptor antagonist. The IC50 values for alpha 1-adrenoceptors (235 nmol/l) and for 5-HT1A receptors (108 nmol/l) lie in the same concentration range. The reduction in blood pressure of anesthetized cats by 8-OH-DPAT and urapidil was completely abolished by spiroxatrine, a 5-HT1A antagonist. However, the decreases in blood pressure induced by naftopidil were only partly antagonized by spiroxatrine.


Subject(s)
Antihypertensive Agents/pharmacology , Naphthalenes/pharmacology , Piperazines/pharmacology , Receptors, Serotonin/drug effects , 8-Hydroxy-2-(di-n-propylamino)tetralin , Animals , Cats , Dioxanes/pharmacology , Dopamine Antagonists , Female , Hemodynamics/drug effects , Male , Radioligand Assay , Rats , Rats, Inbred Strains , Spiro Compounds/pharmacology , Tetrahydronaphthalenes/metabolism
15.
Arzneimittelforschung ; 41(10): 1027-32, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1665973

ABSTRACT

The metabolism of 14C-naftopidil ((R,S)-1-(2-methoxyphenyl)-1-piperazinyl-3- (1-naphthyl-oxy-2-propanol, CAS 57149-07-2) and the pharmacodynamic action of the metabolites was investigated. The metabolic pathway in rat, dog, mouse and man was qualitatively similar, with preference for the hydroxylation of the phenyl or naphthyl moiety of naftopidil [phenyl)hydroxy-metabolite, (naphthyl)hydroxy-metabolite). Cleavage of the parent compound and production of the propylene glycol metabolite was a further important reaction especially for rat and man. In all species investigated, demethylation of naftopidil occurs to a minor extent. O-desmethyl-naftopidil, (phenyl)hydroxy-naftopidil and (naphthyl)hydroxy-naftopidil were found to have similar affinities for the alpha 1-adrenoceptors as the parent compound (IC50)nmol/l): 433.0; 585.0; 52.7; respectively; naftopidil: 235.0). The naftopidil metabolites, like the parent compound showed no alpha 2- or beta-adrenoceptor affinity.


Subject(s)
Naphthalenes/pharmacokinetics , Piperazines/pharmacokinetics , Animals , Bile/metabolism , Biotransformation , Chromatography, Thin Layer , Dogs , Feces/chemistry , Female , Humans , Male , Mass Spectrometry , Mice , Naphthalenes/metabolism , Piperazines/metabolism , Rats , Rats, Inbred Strains , Receptors, Adrenergic, alpha/metabolism , Species Specificity
16.
Arzneimittelforschung ; 41(9): 924-31, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1796920

ABSTRACT

The pharmacokinetics of naftopidil (R,S)-1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthyloxy)-2 propanol, CAS 57149-07-2) was studied in rats and dogs using 14C-labeled drug in pharmacodynamically effective doses (oral doses: 5/10 mg/kg and intravenous doses: 1/2.5 mg/kg in rats/dogs, respectively). Naftopidil (14C) was rapidly and in high extent absorbed in rats and dogs after oral administration. The absolute bioavailability of the parent compound amounted to 9% in rats and indicates a high first pass effect to in part pharmacodynamically effective metabolites, as was shown in a previous paper. The parent compound and its 14C-metabolites were widely distributed into the periphery, more pronounced in the rat than in the dog, as indicated from comparison of the volumes of distribution and dose corrected Cmax- and AUC0-infinity-values in plasma. Elimination of radioactivity from plasma occurred in rat and dog in a similar rate. Tissue distribution studies in the rat showed highest peak-concentrations in the gastrointestinal (GI) tract (evaluated with contents) due to the predominant biliary elimination, followed by liver, adrenals, pituitary and Harderian glands, lungs, pancreas, kidneys, adipose tissue, bone marrow, aorta, thyroid and lymph nodes. Radioactivity was eliminated from most of the tissues within the first 168 h. Highest fractions of the dose were detected--apart from the GI-tract--in liver, muscle, skin, blood, and kidneys. After repeated administration to rats, accumulation of radioactivity in the 28 tissues examined did not exceed factor 9 or factor 5 in most of the tissues.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antihypertensive Agents/pharmacokinetics , Naphthalenes/pharmacokinetics , Piperazines/pharmacokinetics , Administration, Oral , Animals , Antihypertensive Agents/administration & dosage , Bile/metabolism , Biological Availability , Dogs , Feces/chemistry , Female , Injections, Intravenous , Intestinal Absorption , Male , Naphthalenes/administration & dosage , Piperazines/administration & dosage , Pregnancy , Rats , Rats, Inbred Strains , Tissue Distribution
17.
Br J Clin Pharmacol ; 32(1): 69-76, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1888644

ABSTRACT

1. Flupirtine is a novel and, in all probability, centrally acting, analgesic. The present investigation was conducted in order to investigate dose-related effects of perorally administered flupirtine in man, with special regard to specifically analgesic actions, employing a model based on pain-related chemosomatosensory evoked potentials and subjective intensity estimates of painful stimuli. 2. Plasma concentrations of flupirtine measured 2 h after dosing linearly increased as a function of the administered dose. 3. It was possible to reproduce our own previously obtained results, which established the analgesic action of 200 mg flupirtine administered perorally. 4. Intensity estimates linearly decreased as a function of the administered dose, whereas chemosomatosensory evoked potential amplitudes non-linearly changed in relation to the administered dose. 5. In the spontaneous EEG, a dose-dependent increment in the power-spectra was observed, and this mainly in the alpha- and beta-range.


Subject(s)
Aminopyridines/pharmacology , Analgesia , Analgesics/pharmacology , Evoked Potentials, Somatosensory/drug effects , Administration, Oral , Adult , Aminopyridines/administration & dosage , Aminopyridines/blood , Analgesics/administration & dosage , Analgesics/blood , Dose-Response Relationship, Drug , Double-Blind Method , Electroencephalography , Female , Humans , Male , Psychomotor Performance/drug effects
19.
Arzneimittelforschung ; 40(8): 905-8, 1990 Aug.
Article in English | MEDLINE | ID: mdl-1978681

ABSTRACT

Flupirtine (D-9998, Katadolon, CAS 56995-20-1); CAS 56995-20-1), a novel non-opioid analgesic was investigated for possible benzodiazepine-like activities. In receptor binding studies flupirtine and its metabolite were found to reveal no affinity for specific 3H-flunitrazepam binding up to a concentration of 10 mumol/l. In drug discrimination studies, rats were trained to discriminate the novel analgesic flupirtine (10 mg/kg i.p.) from no drug (NaCl 0.9%) under a two-choice fixed-ratio 5 shock-termination schedule. Flupirtine yielded a dose-response curve with an ED50 of 3.9 mg/kg i.p. In generalization tests with a benzodiazepine-type compound lorazepam (0.3 mg/kg, i.p.) did not generalize to the flupirtine training dose. In physical dependence studies using rats, during and after chronic oral administration of flupirtine (2 x 80 mg/kg p.o.) over 45 days no signs of benzodiazepine- and opiate-like physical dependence were observed in rats after withdrawal of the drug. In contrast diazepam (2 x 5 bzw. 2 x 10 mg/kg p.o.) induced typical symptoms of physical dependence. A significant weight loss of the codeine treated animals (2 x 60 mg/kg p.o.) and other typical side effects were also observed after withdrawal of codeine. These results clearly demonstrate that flupirtine has no affinity for benzodiazepine receptors and is free of benzodiazepine or opiate/opioid-like abuse potential.


Subject(s)
Aminopyridines/pharmacology , Analgesics/pharmacology , Anti-Anxiety Agents/pharmacology , Substance-Related Disorders/psychology , Animals , Binding, Competitive/drug effects , Body Weight/drug effects , Brain Chemistry/drug effects , Conditioning, Operant/drug effects , Diazepam/pharmacology , Discrimination Learning/drug effects , Dose-Response Relationship, Drug , Female , Lorazepam/pharmacology , Male , Rats , Rats, Inbred F344 , Rats, Inbred Strains , Receptors, GABA-A/drug effects , Reinforcement Schedule
20.
Arzneimittelforschung ; 40(3): 253-6, 1990 Mar.
Article in English | MEDLINE | ID: mdl-1971750

ABSTRACT

Naftopidil could be characterized by receptor binding studies as an alpha 1-adrenergic antagonist with a binding affinity constant (Ki) of 58.3 nmol/l. both enantiomers of naftopidil revealed similar values, indicating no stereoselective inhibition of 3H-prazosin-binding. An alpha 1-adrenergic radiorecptor assay (RRA) was developed to determine receptor-binding material (parent compound and active metabolites) in the plasma of rats following single oral administration of naftopidil (50 mg/kg). The results indicate a rapid absorption. At the first sampling time (0.5 h) maximum concentration of receptor-binding material was measured. Terminal half-life was calculated with 16.7 h.


Subject(s)
Adrenergic alpha-Antagonists/pharmacokinetics , Naphthalenes/pharmacokinetics , Piperazines/pharmacokinetics , Administration, Oral , Animals , Binding, Competitive , Carrier Proteins/metabolism , Half-Life , Male , Naphthalenes/blood , Piperazines/blood , Prazosin/blood , Radioligand Assay , Rats , Rats, Inbred Strains , Receptors, Adrenergic, alpha/analysis , Receptors, Adrenergic, alpha/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL